Cover Image
市場調查報告書

Neurim Pharmaceuticals Ltd :產品平台分析

Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256093
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Neurim Pharmaceuticals Ltd :產品平台分析 Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015
出版日期: 2015年02月24日 內容資訊: 英文 35 Pages
簡介

Neurim Pharmaceuticals Ltd致力於發現、開發中樞神經相關疾病之治療藥,尤其是高齡性疾病的治療藥。該公司產品治療對象疾病有老年癡呆症及失眠症,左旋多巴誘導性異動症,運動控制障礙,神經性疼痛等。

本報告提供Neurim Pharmaceuticals Ltd 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Neurim Pharmaceuticals Ltd的基本資料

  • Neurim Pharmaceuticals Ltd概要
  • 主要資訊
  • 企業資料

Neurim Pharmaceuticals Ltd :R&D概要

  • 主要的治療範圍

Neurim Pharmaceuticals Ltd :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Neurim Pharmaceuticals Ltd :開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Neurim Pharmaceuticals Ltd :藥物簡介

  • melatonin ER
  • piromelatine
  • Neu-120
  • Neu-107
  • Neu-164
  • Neu-240
  • Neu-AZ1
  • NeuP-12

Neurim Pharmaceuticals Ltd :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Neurim Pharmaceuticals Ltd :最近的開發平台趨勢

Neurim Pharmaceuticals Ltd :暫停中的計劃

Neurim Pharmaceuticals Ltd :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06794CDB

Summary

Global Markets Direct's, 'Neurim Pharmaceuticals Ltd - Product Pipeline Review - 2015', provides an overview of the Neurim Pharmaceuticals Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Neurim Pharmaceuticals Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Neurim Pharmaceuticals Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Neurim Pharmaceuticals Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Neurim Pharmaceuticals Ltd's pipeline products

Reasons to buy

  • Evaluate Neurim Pharmaceuticals Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Neurim Pharmaceuticals Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Neurim Pharmaceuticals Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Neurim Pharmaceuticals Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neurim Pharmaceuticals Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Neurim Pharmaceuticals Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Neurim Pharmaceuticals Ltd Snapshot
    • Neurim Pharmaceuticals Ltd Overview
    • Key Information
    • Key Facts
  • Neurim Pharmaceuticals Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Neurim Pharmaceuticals Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Neurim Pharmaceuticals Ltd - Pipeline Products Glance
    • Neurim Pharmaceuticals Ltd - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Neurim Pharmaceuticals Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Neurim Pharmaceuticals Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Neurim Pharmaceuticals Ltd - Drug Profiles
    • melatonin ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • piromelatine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neu-120
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neu-107
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neu-164
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neu-240
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Neu-AZ1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NeuP-12
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Neurim Pharmaceuticals Ltd - Pipeline Analysis
    • Neurim Pharmaceuticals Ltd - Pipeline Products by Target
    • Neurim Pharmaceuticals Ltd - Pipeline Products by Route of Administration
    • Neurim Pharmaceuticals Ltd - Pipeline Products by Molecule Type
    • Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action
  • Neurim Pharmaceuticals Ltd - Recent Pipeline Updates
  • Neurim Pharmaceuticals Ltd - Dormant Projects
  • Neurim Pharmaceuticals Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Neurim Pharmaceuticals Ltd, Key Information
  • Neurim Pharmaceuticals Ltd, Key Facts
  • Neurim Pharmaceuticals Ltd - Pipeline by Indication, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015
  • Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015
  • Neurim Pharmaceuticals Ltd - Phase III, 2015
  • Neurim Pharmaceuticals Ltd - Phase II, 2015
  • Neurim Pharmaceuticals Ltd - Phase I, 2015
  • Neurim Pharmaceuticals Ltd - Preclinical, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Target, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Route of Administration, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Molecule Type, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline Products by Mechanism of Action, 2015
  • Neurim Pharmaceuticals Ltd - Recent Pipeline Updates, 2015
  • Neurim Pharmaceuticals Ltd - Dormant Developmental Projects,2015
  • Neurim Pharmaceuticals Ltd, Subsidiaries

List of Figures

  • Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Indication, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Stage of Development, 2015
  • Neurim Pharmaceuticals Ltd - Monotherapy Products in Pipeline, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Target, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Neurim Pharmaceuticals Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top